160 related articles for article (PubMed ID: 35514050)
21. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
[TBL] [Abstract][Full Text] [Related]
22. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
Olagunju A; Bolaji O; Amara A; Waitt C; Else L; Adejuyigbe E; Siccardi M; Back D; Khoo S; Owen A
Clin Infect Dis; 2015 Aug; 61(3):453-63. PubMed ID: 25882300
[TBL] [Abstract][Full Text] [Related]
23. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
[TBL] [Abstract][Full Text] [Related]
25. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
[TBL] [Abstract][Full Text] [Related]
26. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
[TBL] [Abstract][Full Text] [Related]
27. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
[TBL] [Abstract][Full Text] [Related]
28. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
[TBL] [Abstract][Full Text] [Related]
29. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R
Clin Pharmacokinet; 2016 Jul; 55(7):861-873. PubMed ID: 26715213
[TBL] [Abstract][Full Text] [Related]
31. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
Gengiah TN; Botha JH; Yende-Zuma N; Naidoo K; Abdool Karim SS
Antivir Ther; 2015; 20(3):297-306. PubMed ID: 25318122
[TBL] [Abstract][Full Text] [Related]
32. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
[TBL] [Abstract][Full Text] [Related]
33. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics.
Martín AS; Gómez AI; García-Berrocal B; Figueroa SC; Sánchez MC; Calvo Hernández MV; Gonzalez-Buitrago JM; Valverde Merino MP; Tovar CB; Martín AF; Isidoro-García M
Pharmacogenomics; 2014 May; 15(7):997-1006. PubMed ID: 24956253
[TBL] [Abstract][Full Text] [Related]
34. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
Bienvenu E; Swart M; Dandara C; Ashton M
Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028
[TBL] [Abstract][Full Text] [Related]
35. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.
Sánchez A; Cabrera S; Santos D; Valverde MP; Fuertes A; Domínguez-Gil A; García MJ;
Antimicrob Agents Chemother; 2011 Nov; 55(11):5314-24. PubMed ID: 21896912
[TBL] [Abstract][Full Text] [Related]
37. Efavirenz pharmacogenetics in a cohort of Italian patients.
Cusato J; Tomasello C; Simiele M; Calcagno A; Bonora S; Marinaro L; Leggieri A; Allegra S; Di Perri G; D'Avolio A
Int J Antimicrob Agents; 2016 Feb; 47(2):117-23. PubMed ID: 26774523
[TBL] [Abstract][Full Text] [Related]
38. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
Adegbola AJ; Rana A; Adeagbo BA; Bolarinwa RA; Olagunju AE; Siccardi M; Owen A; Bolaji OO
Pharmacogenet Genomics; 2020 Jul; 30(5):96-106. PubMed ID: 32209837
[TBL] [Abstract][Full Text] [Related]
39. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
[TBL] [Abstract][Full Text] [Related]
40. Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults.
Meng XM; Li ZR; Zheng XY; Liu YX; Niu WJ; Qiu XY; Lu HZ
Eur J Pharm Sci; 2021 Dec; 167():105986. PubMed ID: 34474119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]